Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

Two drugs commonly known as Mounjaro and Trulicity, will not be available for online sale to non-Canadian residents.

British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

TORONTO, June 10, 2019 /CNW/ - Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 per cent reduction in major cardiovascular events ...

Dulaglutide decreases estimated glomerular filtration rate (eGFR) and proteinuria among youth with type 2 diabetes, according to the results of a study published in Diabetes Care. Youth with type 2 ...

VICTORIA - British Columbia’s Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic. The ...